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ment	 prolonged,	 whereas	 in	 patients	 with	 a	 low	 recurrence	 risk,	
treatment	can	be	stopped	safely.	Several	prediction	models	that	es-
timate	the	risk	of	venous	thromboembolism	recurrence	have	been	





agulation	 factors	 are	 factor	 (F)VIII,	 von	Willebrand	 factor	 (VWF),	
and d-	dimer	for	which	higher	 levels	are	associated	with	 increased	





also	 seems	more	patient-	friendly	as	only	one	 (outpatient)	 contact	




ment.8,9	 Treatment	with	 VKA	 influences	 d-	dimer	 levels,	 probably	










fibrinogen,	 and	VWF:Ag	may	 not.18,19	As	DOACs	 have	 been	 rap-
idly	 implemented	 in	 clinical	 practice,	 it	 is	 of	 importance	 to	 study	
whether	 commonly	 used	measurements	 of	 coagulation	 are	 influ-
enced	by	DOAC	intake.
In	two	crossover	trials,	we	determined	whether	levels	of	FVIII:C,	







trialregister.nl;	 NTR3559).	 In	 the	 study	 by	 Barco	 et	al,	 six	 healthy	





least	15	days.	The	design	 from	 the	Cheung	et	al	 study	was	 similar	
to	the	Barco	et	al	study.	Here,	six	healthy	male	volunteers	received	
twice-	daily	apixaban	10	mg	for	3.5	days	followed	by	a	single	bolus	
of	 prothrombin	 complex	 concentrate	 in	 two	 different	 dosages	 at	






complex	 concentrate),	 in	 total	 there	were	 two	 studies,	 six	 partici-
pants,	three	sessions,	for	a	total	of	36	blood	samples.
2.2 | Blood samples
For	 each	of	 the	 three	 sessions,	 blood	 samples	were	drawn	 imme-
diately	 before	 the	 first	 intake	 of	 rivaroxaban/apixaban	 (T	=	0,	 0′	
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d-	dimer	(imunoturbimetric)	levels	were	measured	using	the	ACL	TOP	
700	analyzer	(Werfen	Instrumentation	Laboratory,	Barcelona,	Spain),	
















Differences	 in	 coagulation	 factor	 levels	before	and	after	 rivaroxa-
ban/apixaban	intake	were	plotted	for	every	participant	and	for	every	
factor	at	the	three	sessions.	We	estimated	the	mean	difference	with	
95%	 confidence	 intervals	 (CIs)	 in	 levels	 of	 the	 coagulation	 factors	
(before	and	after	the	intake	of	rivaroxaban/apixaban)	for	every	par-
ticipant	at	the	three	different	sessions	(within	pair	comparison).	The	
observed	mean	of	 these	paired	differences	 are	presented	both	 as	
absolute	differences	and	as	percentages.	d-	dimer	was	also	assessed	







3  | RESULTS AND DISCUSSION
The	clinical	characteristics	of	the	participants	and	the	mean	 levels	
of	 the	 coagulation	 factors	 at	 the	 start	 of	 each	 session	 are	 shown	





Figure	1	 depicts	 the	 difference	 in	 coagulant	 factor	 levels	 be-








dL	 (95%	CI	−43;	−1)	 for	FXII:C,	−0.11	g/L	 (95%	CI	−0.25;	0.03)	 for	
fibrinogen,	 −7	IU/dL	 (95%	CI	 −18;	 3)	 for	VWF:Ag,	 −27	 FEU	ng/mL	
(95%	CI	−50;	−4)	 for	d-	dimer	and	−0.36	 (95%	CI	−0.57;	−0.15)	 for	






−19	IU/dL	 (95%	 CI	 −24;	 −15)	 for	 FXII:C,	 −0.18	g/L	 (95%	 CI	 −0.33;	
0.03)	for	fibrinogen,	−52	FEU	ng/mL	(95%	CI	−100;	−4)	for	d-	dimer,	
−0.25	 (−0.60;	0.09)	 for	 Ln	d-	dimer,	 and	1	IU/dL	 (95%	CI	−7;	9)	 for	







































Finally,	 we	 assessed	 whether	 there	 was	 a	 linear	 relation-
ship	 between	 measured	 FVIII:C	 and	 d-	dimer	 levels	 before	 and	
after	 rivaroxaban/apixaban	 intake.	 As	 depicted	 in	 Figure	2A,	
we	 observed	 a	 linear	 association	 between	 FVIII:C	 levels	 before	
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As	 also	 reported	 by	 Tichelaar	 and	 colleagues,11	 FVIII:C	 mea-
surements	seem	to	be	affected	by	rivaroxaban	intake.	We	observed	
the	same	effect	for	FXI:C	and	FXII:C	measurements	for	both	rivar-
oxaban	 and	 apixaban	 intake.	 As	 was	 also	 reported	 by	Mani	 et	al,	
VWF:Ag	measurements	did	not	seem	to	be	affected	by	a	low	dose	





enriched	samples	of	rivaroxaban	and	apixaban.19 In other studies in 
which	factor	Xa	inhibitors	were	added	to	human	plasma	ex	vivo,	fi-
brinogen	measurements	were	reported	not	to	be	affected.17-19 Our 
study	confirm	 these	 findings	 in	healthy	men	on	 therapeutic	doses	











sessions	 (with	 a	washout	period	 in	between)	blood	was	 taken	 im-
mediately	before	rivaroxaban/apixaban	intake	and	three	hours	after	
intake.	Where	most	previous	studies	were	 limited	 to	ex	vivo	or	 in	
TABLE  2 Effects	of	rivaroxaban	and	apixaban	on	coagulation	factor	measurements
Mean (SD) FVIII:C FXI:C FXII:C Fibrinogen VWF:Ag d- dimer Ln d- dimer
Rivaroxaban
T	=	0 112	(20) 108	(15) 122	(18) 2.75	(0.92) 99	(28) 117	(54) 4.59	(0.78)
T	=	1 74	(19) 79	(11) 100	(23) 2.64	(0.93) 91	(27) 90	(36) 4.23	(0.94)
Mean 
differencea





T	=	0 114	(12) 120	(11) 104	(36) 2.56	(0.36) 109	(16) 164	(103) 4.84	(0.78)
T	=	1 84	(6) 91	(14) 84	(33) 2.38	(0.25) 110	(12) 112	(65) 4.58	(0.54)
Mean 
differencea
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vitro	settings,	we	investigated	the	effects	of	rivaroxaban/apixaban	





vitro study d-	dimer	measurements	were	not	 influenced	by	enrich-
ing	 samples	with	 rivaroxaban	or	 apixaban.19	 In	 addition,	 all	 partic-
ipants	were	men	hereby	 limiting	 the	generalizability	of	 the	 results	
to women.
The	 results	 of	 our	 study	 are	 relevant	 to	 clinical	 practice:	
d-	dimer,	 FVIII:C,	 FXI:C,	 and	 FXII:C	 measurements	 in	 patients	
using	 rivaroxaban	or	apixaban	should	be	 interpreted	with	cau-
tion	 as	 they	 are	 probably	 different	 from	 as	 when	 measured	
without	 rivaroxaban/apixaban	use.	As	 there	was	a	 linear	asso-
ciation	 in	 the	decrease	of	FVIII:C	measurement	after	 intake	of	
rivaroxaban/apixaban,	 FVIII:C	might	 still	 be	 a	 useful	 predictor	
while	using	rivaroxaban	or	apixaban,	however,	this	requires	fur-
ther	validation.	VWF:Ag	was	hardly,	 if	at	all,	 influenced	by	the	
treatment	 and	 was	 previously	 found	 to	 have	 a	 similar	 predic-
tive	 performance	 to	 FVIII:C	 in	 the	MEGA	 follow-	up	 study.5 In 
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